Use of prostate cancer cells as in vitro model for discovering miRNAs released by cells that developed docetaxel resistance

Autor: L. Bascetta(1), M. Rizzo (1), M. Evangelista (1), G. Rainaldi (1), A. Mercatanti (1), R. D'Aurizio (2), F. Russo (2), M. Pellegrini (2), A. Altavilla (3), S. Bracarda (3)

Publikováno v: European Association on cancer Research (EACR-AACR-SIC )Special Conference 2015. Anticancer drug action and drug resistance: from cancer biology to the clinic, pp. 1–1, Florence, Italy, 17-23/10/2015
info:cnr-pdr/source/autori:L. Bascetta(1), M. Rizzo (1), M. Evangelista (1), G. Rainaldi (1), A. Mercatanti (1), R. D'Aurizio (2), F. Russo (2), M. Pellegrini (2), A. Altavilla (3), S. Bracarda (3),/congresso_nome:European Association on cancer Research (EACR-AACR-SIC )Special Conference 2015. Anticancer drug action and drug resistance: from cancer biology to the clinic/congresso_luogo:Florence, Italy/congresso_data:17-23%2F10%2F2015/anno:2015/pagina_da:1/pagina_a:1/intervallo_pagine:1–1

One of the major problems in androgen-independent prostate cancer (PCa), nowadays de ned castration resistant prostate cancer (CRPC), is the development of resistance to docetaxel (DCT). Considering the availability of new therapeutic agents it would

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=cnr_________::4efd2c35619ce40a2a6a08f2c60d75ad
https://publications.cnr.it/doc/348387